Project Description

Author: Tory et al.

Summary:

Introduction: Emicizumab, is a monoclonal antibody that bridges activated factor IX (FIX) and factor X (FX) to replace the function of missing activated factor VIII (FVIII) in hemophilia A patients irrespective of FVIII inhibitor status. Aim: This study assessed the effectiveness of Emicizumab in preventing bleeding episodes in patients with Hemophilia A. This quasi-experimental study included patients with moderate to severe hemophilia A who were undergoing episodic FVIII replacement therapy. The primary end point was the difference in annualized bleeding rates (ABR) and the secondary endpoint was the difference in hemophilia joint health score (HJHS) before and after emicizumab prophylaxis. A total of 30 male hemophilia patients were included, the mean age was 16.7 (± 8.1) (SD) years and most of them had moderate hemophilia A (63.3%). Before prophylaxis, the median ABR was 48(IQR:35-60) and 93.3% of patients had ABR >8 whereas after prophylaxis the median ABR decreased significantly [(median(IQR): 0 (0.0-0.4), p<0.001], and 56.7% had zero bleeds. ABR was not significantly different in patient with and without FVIII inhibitors. The HJHS scored significantly improved after prophylaxis (10 vs 2.5, p<0.001). The bleeding events were reduced significantly (23 vs 0.0, p<0.001) and zero new target joints were reported after prophylaxis. Most of the patients (93.3%) did not face any serious adverse events after prophylaxis. Conclusion: Emicizumab prophylaxis was associated with a significantly lower rate of bleeding events among participants with hemophilia A, regardless of inhibitor status.

Status: Ongoing

Full text link: Not available